| Literature DB >> 33447427 |
Jinlan Bao1, Shaoxin Zheng1, Canxia Huang2, Jun Tao3, Ying Tang1, Runlu Sun1, Qi Guo1, Jingfeng Wang1, Yuling Zhang1.
Abstract
BACKGROUND: Type A acute aortic dissection (TA-AAD) has high mortality, with 50% of patients dying before hospital admission. Hypertension is the most common comorbidity for acute aortic dissection, and effective antihypertensive therapy is still unable to predict the risk of aortic rupture at the medium- and long-term stages. While the presence of renal cyst has been found to increases the risk of thoracic aortic disease, the correlation between renal cyst and TA-AAD with hypertension remains poorly understood. Thus, this study aimed to determine the relationship of renal cyst and TA-AAD with hypertension.Entities:
Keywords: Type A acute aortic dissection (TA-AAD); hypertension; renal cyst
Year: 2020 PMID: 33447427 PMCID: PMC7797828 DOI: 10.21037/jtd-20-3422
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Comparison of baseline characteristics between the AD with hypertension and non-AD with hypertension groups
| Characteristic | AD with hypertension group (N=230) | Non-AD with hypertension group (N=234) | P |
|---|---|---|---|
| Age, years | 53.79±11.31 | 53.75±10.89 | 0.970 |
| Male, n (%) | 209 (90.87) | 211 (90.17) | 0.875 |
| Hypertension optimal control, n (%) | 123 (53.48) | 135 (57.69) | 0.401 |
| Normal max SBP, mmHg | 189.26±15.25 | 192.0±19.39 | 0.091 |
| Normal max DBP, mmHg | 109.52±10.31 | 109.58±10.01 | 0.949 |
| Previous AD history, n (%) | 4 (1.74) | 0 | – |
| Previous AD therapy history, n (%) | 4 (1.74) | 0 | – |
| Diabetes, n (%) | 32 (13.91) | 33 (14.10) | 1.0 |
| Hyperlipidemia, n (%) | 31 (3.48) | 19 (8.12) | 0.073 |
| Smoking history, n (%) | 81 (35.22) | 87 (37.18) | 0.7 |
| Alcohol history, n (%) | 24 (10.43) | 27 (11.54) | 0.767 |
| Cerebral infarction history, n (%) | 10 (4.35) | 11 (4.70) | 1.0 |
| Kidney stone history, n (%) | 10 (4.35) | 13 (5.56) | 0.670 |
| CHD history, n (%) | 12 (5.22) | 13 (5.56) | 1.0 |
| Hyperuricemia, n (%) | 8 (3.48) | 14 (5.98) | 0.275 |
| Hypertension family history, n (%) | 84 (36.52) | 83 (35.47) | 0.847 |
| AD family history, n (%) | 2 (0.87) | 1 (0.43) | 0.621 |
| AAO, mm | 41.56±8.06 | 34.46±4.74 | <0.001 |
| LA, mm | 36.34±4.49 | 36.18±4.69 | 0.708 |
| IVSD, mm | 11.70±1.60 | 10.53±1.75 | <0.001 |
| LVDD, mm | 50.75±4.74 | 48.97±4.12 | <0.001 |
| LVPWD, mm | 11.55±1.77 | 10.45±1.70 | <0.001 |
| EF% | 65.40±5.75 | 66.23±5.17 | 0.104 |
| TC, mmol/L | 4.86±1.23 | 5.08±1.10 | 0.040 |
| TG, mmol/L | 1.51±0.91 | 1.68±0.92 | 0.039 |
| HDL-C, mmol/L | 1.21±0.35 | 1.25±0.35 | 0.225 |
| LDL-C, mmol/L | 3.09±0.88 | 3.21±0.84 | 0.120 |
| apoA1, mmol/L | 1.22±0.29 | 1.25±0.23 | 0.246 |
| apoB, mmol/L | 0.89±0.25 | 0.93±0.24 | 0.076 |
| FBG, mmol/L | 5.84±1.39 | 5.62±1.68 | 0.129 |
| Uric acid, mmol/L | 431.94±105.99 | 410.46±99.18 | 0.182 |
| Creatinine, umol/L | 109.98±40.84 | 97.74±43.23 | 0.064 |
| Renal cyst, n (%) | |||
| No renal cyst | 100 (43.48) | 164 (70.09) | <0.001 |
| Single renal cyst | 79 (34.35)* | 50 (21.37) | |
| Multiple renal cysts | 51 (22.17)* | 20 (8.55) |
Renal cyst association with type A acute aortic dissection with hypertension. *, compared with no renal cyst, P<0.001. AD, aortic dissection; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHD, coronary heart disease; AAO, ascending aorta; LA, left atrium; IVSD, ventricular septum dimension; LVDD, left ventricular end diastolic dimension; LVPWD, left ventricular posterior-wall dimension; EF, left ventricular ejection fraction; TC, total cholesterol; TG, triglyceride ; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; FBG, fast blood glucose.
Comparison of baseline characteristics of males and females between the AD with hypertension and the non-AD with hypertension groups
| Characteristics | AD with hypertension | Non-AD with hypertension | P | |||
|---|---|---|---|---|---|---|
| Male (N=209) | Female (N=21) | Male (N=211) | Female (N=23) | |||
| Age, years | 53.40±11.52 | 57.67±8.20 | 53.65±11.20 | 54.65±7.56 | 0.145 | |
| Hypertension optimal control, n (%) | 109 (52.15) | 14 (66.67) | 118 (55.92) | 17 (73.91)* | 0.039 | |
| Normal max SBP, mmHg | 189.98±15.21 | 182.05±14.07 | 193.18±19.71* | 181.17±11.70 | <0.001 | |
| Normal max DBP, mmHg | 110.21±10.04 | 102.71±8.57 | 109.96±10.12 | 106.13±8.37* | <0.001 | |
| Previous AD history, n (%) | 4 (1.91) | 0 | 0 | 0 | – | |
| Previous AD therapy history, n (%) | 4 (1.91) | 0 | 0 | 0 | – | |
| Diabetes, n (%) | 29 (13.88) | 3 (14.29) | 30 (14.22) | 3 (13.04) | 1.0 | |
| Hyperlipidemia, n (%) | 26 (12.44) | 5 (23.81) | 17 (8.06) | 2 (8.70) | 0.302 | |
| Smoking history, n (%) | 74 (35.41) | 7 (33.33) | 87 (41.23) | 1 (4.35) | 0.008 | |
| Alcohol history, n (%) | 22 (10.53) | 2 (9.52) | 27 (12.80) | 1 (4.35) | 0.454 | |
| Cerebral infarction history, n (%) | 10 (4.78) | 0 | 11 (5.21) | 1 (4.35) | 0.710 | |
| Kidney stone history, n (%) | 9 (4.31) | 1 (4.76) | 13 (6.16) | 1 (4.35) | 0.716 | |
| CHD history, n (%) | 11 (5.26) | 1 (4.76) | 12 (5.69) | 1 (4.35) | 1.0 | |
| Hyperuricemia, n (%) | 7 (3.35) | 1 (4.76) | 12 (5.69) | 2 (8.70) | 0.453 | |
| Hypertension family history, n (%) | 76 (36.36) | 8 (38.10) | 74 (35.07) | 9 (39.13) | 0.742 | |
| AD family history, n (%) | 2 (0.96) | 0 | 1 (0.47) | 0 | – | |
| AAO, mm | 41.67±8.14 | 40.48±7.30 | 34.39±4.71 | 35.04±5.0 | 0.750 | |
| LA, mm | 36.33±4.41 | 36.48±5.41 | 36.11±4.72 | 36.78±4.43 | 0.566 | |
| IVSD, mm | 11.69±1.61 | 11.81±1.60 | 10.53±1.77 | 10.57±1.62 | 0.860 | |
| LVDD, mm | 50.72±4.74 | 51±4.74 | 48.91±4.06 | 49.48±4.78 | 0.584 | |
| LVPWD, mm | 11.56±1.81 | 11.52±1.33 | 10.45±1.72 | 10.48±1.56 | 0.937 | |
| EF% | 65.54±5.75 | 64.05±5.73 | 66.31±5.09 | 65.52±5.88 | 0.202 | |
| TC, mmol/L | 4.82±1.23 | 5.29±1.21 | 5.07±1.09 | 5.23±1.17 | 0.088 | |
| TG, mmol/L | 1.47±0.81 | 1.91±1.52 | 1.70±0.92 | 1.56±0.92 | 0.310 | |
| HDL-C, mmol/L | 1.19±0.34 | 1.35±0.33 | 1.25±0.36 | 1.23±0.22 | 0.215 | |
| LDL-C, mmol/L | 3.07±0.88 | 3.30±0.82 | 3.20±0.82 | 3.29±0.98 | 0.233 | |
| apoA1, mmol/L | 1.21±0.28 | 1.34±0.28 | 1.25±0.23 | 1.24±0.19 | 0.148 | |
| apoB, mmol/L | 0.89±0.25 | 0.90±0.23 | 0.93±0.24 | 0.97±0.30 | 0.442 | |
| FBG, mmol/L | 5.86±1.41 | 5.66±1.14 | 5.60±1.66 | 5.79±1.88 | 0.993 | |
| Uric acid, mmol/L | 396.05±116.65 | 371±99.66 | 377.37±105.79 | 381.83±102.34 | 0.568 | |
| Creatinine, umol/L | 91.27±32.22 | 96.81+53.88 | 87.11±32.17 | 81.04±18.83 | 0.993 | |
| Renal cyst, n (%) | ||||||
| No renal cyst | 91 (43.54) | 9 (42.86) | 147 (69.67) | 17 (73.91) | 0.686 | |
| Single renal cyst | 73 (34.93) | 6 (28.57) | 46 (21.80) | 4 (17.39) | ||
| Multiple renal cysts | 45 (21.53) | 6 (28.57) | 18 (8.53) | 2 (8.70) | ||
*, compared to AD with hypertension, P<0.05. AD, aortic dissection; SBP, SBP, systolic blood pressure; DBP, diastolic blood pressure; CHD, coronary heart disease; AAO, ascending aorta; LA, left atrium; IVSD, ventricular septum dimension; LVDD, left ventricular end diastolic dimension; LVPWD, left ventricular posterior-wall dimension; EF, left ventricular ejection fraction; TC, total cholesterol; TG, triglyceride ; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; FBG, fast blood glucose.
Comparison of baseline characteristics in the three renal cyst subgroups
| Characteristics | AD with hypertension | Non-AD with hypertension | |||||||
|---|---|---|---|---|---|---|---|---|---|
| No renal cyst group (N=100) | Single renal cyst group (N=79) | Multiple renal cyst group (N=51) | P | No renal cyst group (N=164) | Single renal cyst group (N=50) | Multiple renal cyst group (N=20) | P | ||
| Age, years | 53.78±10.46 | 51.57±10.75 | 57.25±13.00* | 0.019 | 53.96±10.83 | 52.72±11.17 | 54.65±11.05 | 0.727 | |
| Male, n (%) | 91 (91.0) | 73 (92.41) | 45 (88.24) | 0.721 | 147 (89.63) | 46 (92) | 18 (90.0) | 00.886 | |
| Hypertension optimal control, n (%) | 48 (48.0) | 41 (51.90) | 34 (66.67) | 0.088 | 92 (56.10) | 28 (56) | 15 (75.0) | 0.261 | |
| Normal max SBP, mmHg | 191.80±14.77 | 186.72±14.55 | 188.20±16.69 | 0.073 | 192.80+19.77 | 190.70±16.57 | 188.75±23.02 | 0.589 | |
| Normal max DBP, mmHg | 109.98±10.54 | 108.78±9.50 | 109.76±10.38 | 0.723 | 110.0±10.36 | 108.62±9.46 | 108.55±8.44 | 0.620 | |
| Previous AD history, n (%) | 2 (2.0) | 0 | 2 (3.92) | – | 0 | 0 | 0 | – | |
| Previous AD therapy history, n (%) | 2 (2.0) | 0 | 2 (3.92) | – | 0 | 0 | 0 | – | |
| Diabetes, n (%) | 13 (13.0) | 16 (20.25) | 4 (7.84) | 0.126 | 27 (16.46) | 4 (8.0) | 2 (10.0) | 0.277 | |
| Hyperlipidemia, n (%) | 11 (11.0) | 13 (16.46) | 6 (11.76) | 0.535 | 16 (9.76) | 3 (6.0) | 0 | – | |
| Smoking history, n (%) | 41 (41.0) | 25 (31.65) | 15 (29.41) | 0.264 | 67 (40.85) | 14 (28.0) | 7 (35.0) | 0.251 | |
| Alcohol history, n (%) | 9 (9.0) | 7 (8.86) | 8 (15.69) | 0.380 | 17 (10.37) | 7 (14.0) | 4 (20.0) | 0.402 | |
| Cerebral infarction history, n (%) | 4 (4.0) | 4 (5.06) | 2 (3.92) | 0.928 | 6 (3.66) | 3 (6.0) | 3 (15.0) | 0.090 | |
| Kidney stone history, n (%) | 3 (3.0) | 5 (6.33) | 2 (3.92) | 0.548 | 10 (6.10) | 3 (6.0) | 1 (5.0) | 0.981 | |
| CHD history, n (%) | 7 (7.0) | 2 (2.53) | 3 (5.88) | 0.398 | 10 (6.10) | 1 (2.0) | 2 (10.0) | 0.359 | |
| Hyperuricemia, n (%) | 2 (2.0) | 4 (5.06) | 2 (3.92) | 0.529 | 13 (7.93) | 0 | 1 (5.0) | – | |
| Hypertension family history, n (%) | 39 (39.0) | 28 (35.44) | 17 (33.33% | 0.768 | 62 (37.80) | 18 (36.0) | 3 (15.0) | 0.131 | |
| AD family history, n (%) | 1 (1.0) | 0 | 1 (1.96) | – | 1 (0.61) | 0 | 0 | – | |
| AAO, mm | 41.89±7.56 | 41.81±8.62 | 40.53±8.17 | 0.585 | 34.42±4.50 | 34.82±5.32 | 33.85±5.27 | 0.731 | |
| LA, mm | 35.95±4.33 | 36.53±4.73 | 36.80±4.45 | 0.489 | 36.15±4.76 | 36.50±4.70 | 35.60±4.17 | 0.763 | |
| IVSD, mm | 11.70±1.64 | 11.76±1.69 | 11.63±1.40 | 0.900 | 10.46±1.77 | 10.88±1.76 | 10.30±1.56 | 0.270 | |
| LVDD, mm | 51.18±5.42 | 50.32±4.24 | 50.57±4.74 | 0.460 | 48.91±3.96 | 49.36±4.26 | 5.17±1.16 | 0.653 | |
| LVPWD, mm | 11.56±2.11 | 11.66±1.51 | 11.37±1.39 | 0.668 | 10.34±1.68 | 10.88±1.78 | 10.30±1.53 | 0.133 | |
| EF% | 65.92±5.65 | 64.96±6.54 | 65.08±4.55 | 0.490 | 66.49±5.03 | 65.32±5.86 | 66.40±4.33 | 0.373 | |
| TC, mmol/L | 4.76±1.14 | 4.50±1.33 | 4.87±1.23 | 0.457 | 5.10±1.10 | 5.03±1.12 | 5.12±1.06 | 0.913 | |
| TG, mmol/L | 1.45±0.80 | 1.48±0.83 | 1.66±1.18 | 0.373 | 1.68±0.90 | 1.65±0.94 | 1.74±1.10 | 0.940 | |
| HDL-C, mmol/L | 1.17±0.30 | 1.25±0.39 | 1.20±0.35 | 0.311 | 1.24±0.38 | 1.27±0.27 | 1.22±0.26 | 0.833 | |
| LDL-C, mmol/L | 3.04±0.83 | 3.18±0.92 | 3.04±0.90 | 0.518 | 3.21±0.84 | 3.20±0.88 | 3.24±0.71 | 0.983 | |
| apoA1, mmol/L | 1.19±0.29 | 1.26±0.29 | 1.21±0.27 | 0.264 | 1.24±0.24 | 1.27±0.19 | 1.26±0.16 | 0.747 | |
| apoB, mmol/L | 0.88±0.25 | 0.92±0.26 | 0.87±0.24 | 0.368 | 0.94±0.25 | 0.91±0.25 | 0.92±0.21 | 0.786 | |
| FBG, mmol/L | 5.97±1.61 | 5.82±1.26 | 5.60±1.05 | 0.299 | 5.65±1.75 | 5.62±1.27 | 5.32±2.06 | 0.705 | |
| Uric acid, mmol/L | 379.49±112.34 | 407.80±115.76 | 400.02±119.03 | 0.241 | 376.65±108.50 | 382.90±100.30 | 374.50±93.84 | 0.925 | |
| Creatinine, umol/L | 91.48±33.00 | 92.46±41.18 | 91.29±26.29 | 0.977 | 87.78±33.67 | 84.96±23.83 | 80.0±25.19 | 0.531 | |
*, compared with single renal cyst, P<0.05. AD, aortic dissection; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHD, coronary heart disease; AAO, ascending aorta; LA, left atrium; IVSD, ventricular septum dimension; LVDD, left ventricular end diastolic dimension; LVPWD, left ventricular posterior-wall dimension; EF, left ventricular ejection fraction; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; FBG, fast blood glucose.
Comparison of baseline characteristics in the three age groups
| Characteristics | AD with hypertension | Non-AD with hypertension | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Young group (N=29) | Middle-aged group (N=128) | Elderly group (N=73) | P | Young group (N=22) | Middle-aged group (N=138) | Elderly group (N=74) | P | ||
| Age, years | 34.52±3.75 | 50.90±5.20*# | 66.52±4.99* | <0.001 | 35.82±4.31 | 50.05±5.99*# | 65.99±5.59* | <0.001 | |
| Male, n (%) | 29 (100.0) | 117 (91.41) | 63 (86.3) | – | 22 (100.0) | 120 (86.96) | 69 (93.24) | – | |
| Hypertension optimal control, n (%) | 56 (50.91) | 41 (51.90) | 26 (63.41) | 0.368 | 13 (59.10) | 83 (60.14) | 39 (52.70) | 0.573 | |
| Normal max SBP, mmHg | 187.55±14.34 | 190.20±15.33 | 188.27±15.53 | 0.562 | 194.23±21.67 | 190.61±19.16 | 193.95±19.17 | 0.419 | |
| Normal max DBP, mmHg | 108.55±10.31 | 110.21±10.21 | 108.70±9.95 | 0.513 | 111.73±12.24 | 109.75±9.21 | 108.64±10.73 | 0.427 | |
| Previous AD history, n (%) | 1 (3.45) | 0 | 3 (4.11) | – | 0 | 0 | 0 | – | |
| Previous AD therapy history, n (%) | 1 (3.45) | 0 | 3 (4.11) | – | 0 | 0 | 0 | – | |
| Diabetes, n (%) | 2 (6.90) | 6 (4.69) | 24 (32.88) | 0.052 | 0 | 19 (13.77) | 14 (18.92) | – | |
| Hyperlipidemia, n (%) | 2 (6.90) | 8 (6.25) | 21 (28.77) | 0.299 | 2 (9.10) | 9 (6.52) | 8 (10.81) | 0.544 | |
| Smoking history, n (%) | 14 (48.28) | 25 (19.53) | 42 (57.53) | 0.283 | 8 (36.36) | 56 (40.58) | 24 (32.43) | 0.502 | |
| Alcohol history, n (%) | 4 (13.79) | 9 (7.03) | 11 (15.07) | 0.579 | 1 (4.55) | 17 (12.32) | 10 (13.51) | 0.513 | |
| Cerebral infarction history, n (%) | 0 | 3 (2.34) | 7 (9.59) | – | 1 (4.55) | 7 (5.07) | 4 (5.41) | 0.986 | |
| Kidney stone history, n (%) | 2 (6.90) | 3 (2.34) | 5 (6.85) | 0.770 | 1 (4.55) | 9 (6.52) | 4 (5.41) | 0.907 | |
| CHD history, n (%) | 0 | 4 (3.13) | 8 (10.96) | – | 0 | 8 (5.80) | 5 (6.76) | – | |
| Hyperuricemia, n (%) | 2 (6.90) | 1 (0.78) | 5 (6.85) | 0.360 | 1 (4.55) | 11 (7.97) | 2 (2.70) | 0.291 | |
| Hypertension family history, n (%) | 12 (41.38) | 24 (32.88) | 48 (65.75) | 0.682 | 9 (40.91) | 48 (34.78) | 26 (35.14) | 0.854 | |
| AD family history, n (%) | 0 | 1 (0.78) | 1 (1.37) | – | 1 (4.55) | 0 | 0 | – | |
| AAO, mm | 41.24±8.42 | 41.81±8.32 | 41.25±7.52 | 0.870 | 34.41±5.26 | 34.65±4.74 | 34.11±4.54 | 0.728 | |
| LA, mm | 35.10±3.82 | 36.79±4.63 | 36.04±4.44 | 0.150 | 34.50±3.71 | 36.22±4.68 | 36.59±4.90 | 0.181 | |
| IVSD, mm | 12.24±1.66 | 11.62±1.65 | 11.64±1.48 | 0.154 | 10.27±2.21 | 10.61±1.77 | 10.47±1.56 | 0.662 | |
| LVDD, mm | 51.07±4.27 | 50.77±4.98 | 50.58±4.52 | 0.890 | 48.23±4.05 | 49.28±4.17 | 48.61±4.06 | 0.362 | |
| LVPWD, mm | 11.90±2.43 | 11.51±1.81 | 11.49±1.36 | 0.534 | 10.32±2.32 | 10.51±1.66 | 10.38±1.57 | 0.795 | |
| EF% | 63.03±5.88 | 65.59±5.86 | 66.01±5.33 | 0.052 | 65.50±5.64 | 66.35±4.96 | 66.23±5.46 | 0.776 | |
| TC, mmol/L | 4.90±1.04 | 4.87±1.28 | 4.83±1.23 | 0.958 | 5.0±0.96 | 5.08±1.11 | 5.11±1.12 | 0.916 | |
| TG, mmol/L | 1.65±1.13 | 1.54±0.86 | 1.40±0.88 | 0.375 | 1.82±0.79 | 1.68±0.95 | 1.64±0.91 | 0.725 | |
| HDL-C, mmol/L | 1.15±0.21 | 1.21±0.37 | 1.23±0.34 | 0.534 | 1.19±0.28 | 1.23±0.36 | 1.29±0.36 | 0.401 | |
| LDL-C, mmol/L | 3.11±0.80 | 3.10±0.89 | 3.05±0.90 | 0.929 | 3.18±0.76 | 3.22±0.87 | 3.20±0.82 | 0.965 | |
| apoA1, mmol/L | 1.19±0.24 | 1.23±0.29 | 1.22±0.29 | 0.818 | 1.16±0.25 | 1.25±0.22 | 1.28±0.22 | 0.101 | |
| apoB, mmol/L | 0.87±0.25 | 0.88±0.25 | 0.90±0.25 | 0.834 | 0.86±0.21 | 0.94±0.25 | 0.94±0.25 | 0.343 | |
| FBG, mmol/L | 5.84±1.35 | 5.96±1.51 | 5.62±1.16 | 0.242 | 4.99±0.89 | 5.54±1.42 | 5.96±2.19 | 0.040 | |
| Uric acid, mmol/L | 416.72±152.67# | 405.07±115.77# | 364.83±90.79 | 0.030 | 421.74±160.19 | 369.22±96.59 | 380.76±98.66 | 0.090 | |
| Creatinine, umol/L | 82.79±25.31 | 95.14±38.48 | 89.44±29.92 | 0.175 | 88.27±25.28 | 83.81±30.44 | 91.05±33.69 | 0.262 | |
*, compared with the younger age group, P<0.05; #, compared with the elderly group, P<0.05. AD, aortic dissection; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHD, coronary heart disease; AAO, ascending aorta; LA, left atrium; IVSD, ventricular septum dimension; LVDD, left ventricular end diastolic dimension; LVPWD, left ventricular posterior-wall dimension; EF, left ventricular ejection fraction; TC, total cholesterol; TG, triglyceride ; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; FBG, fast blood glucose.
Figure 1DeBakey I/DeBakey II classification for renal cyst and age subgroups. (A) The number of DeBakey I/DeBakey II cases differed across the three renal cyst subgroups (P=0.042), compare with the single renal cyst subgroup, no renal cyst subgroup having significantly more DeBakey II cases (19% vs. 6.33%, P=0.015). (B) There was no difference in DeBakey I/DeBakey II classification across the different age subgroups (P=0.814).
Figure 2Type A aortic dissection tear length in the renal cyst and age subgroups. (A) The ending point differed across the three renal cyst subgroups (P=0.002; *, significantly different compared with the ascending aorta); (B) there was no difference in dissection ending points across the three age subgroups (P=0.273).
Multiple logistic regression analysis relationship between renal cyst and the risk of TA-AAD in different sex group
| Characteristics | All participants | Male | Female | |||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |||
| AAO | 1.171 (1.124, 1.220) | <0.001 | 1.176 (1.126, 1.228) | <0.001 | 1.204 (1.005, 1.442) | 0.044 | ||
| IVSD | 1.303 (1.026, 1.656) | 0.030 | 1.280 (0.999, 1.640) | 0.051 | 3.339 (0.480, 23.200) | 0.223 | ||
| LVDD | 0.996 (0.943, 1.053) | 0.898 | 1.001 (0.944, 1.061) | 0.981 | 0.948 (0.789, 1.138) | 0.566 | ||
| LVPWD | 1.006 (0.805, 1.257) | 0.959 | 1.013 (0.807, 1.273) | 0.911 | 0.421 (0.047, 3.781) | 0.440 | ||
| TC | 0.901 (0.744, 1.112) | 0.356 | 0.902 (0.729, 1.116) | 0.342 | 0.997 (0.507, 1.962) | 0.993 | ||
| TG | 0.814 (0.615, 1.077) | 0.150 | 0.715 (0.517, 0.987) | 0.042 | 1.362 (0.609, 3.046) | 0.452 | ||
| No renal cyst | 0.188 (0.095, 0.372) | <0.001 | 0.185 (0.090, 0.381) | <0.001 | 0.532 (0.043, 6.640) | 0.624 | ||
| Single renal cyst | 0.448 (0.214, 0.939) | 0.033 | 0.454 (0.209, 0.986) | 0.046 | 0.967 (0.056, 16.805) | 0.982 | ||
| Multiple renal cysts | 1 | – | 1 | – | 1 | – | ||
Adjusted for AAO, IVSD, LVDd, LVPWD, TC, TG. A P value ≤0.05 was considered as statistically significant. TA-AAD, type A acute aortic dissection; AAO, ascending aorta; IVSD, ventricular septum dimension; LVDD, left ventricular end diastolic dimension; LVPWD, left ventricular posterior-wall dimension; TC, total cholesterol; TG, triglyceride.
The relationship between renal cyst and the risk of TA-AAD in the three renal cyst subgroups according to multiple logistic regression analysis
| Characteristics | Young | Middle-aged | Elderly | |||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P Value | OR (95% CI) | P Value | OR (95% CI) | P Value | |||
| AAO | 1.147 (0.986, 1.335) | 0.075 | 1.157 (1.101, 1.216) | <0.001 | 1.243 (1.130, 1.368) | <0.001 | ||
| IVSD | 2.024 (1.026, 3.995) | 0.042 | 1.153 (0.835, 1.592) | 0.387 | 1.393 (0.680, 2.853) | 0.365 | ||
| LVDD | 1.147 (0.923, 1.426) | 0.217 | 1.00 (0.933, 1.072) | 0.996 | 0.962 (0.857, 1.079) | 0.508 | ||
| LVPWD | 0.816 (0.504, 1.320) | 0.407 | 1.032 (0.754, 1.414) | 0.843 | 1.177 (0.581, 2.386) | 0.651 | ||
| TC | 0.952 (0.358, 2.532) | 0.922 | 0.970 (0.753, 1.249) | 0.812 | 0.656 (0.439, 0.981) | 0.040 | ||
| TG | 0.526 (0.189, 1.465) | 0.219 | 0.866 (0.601, 1.248) | 0.442 | 0.891 (0.542, 1.463) | 0.647 | ||
| No renal cyst | 0.064 (0.004, 1.0) | 0.050 | 0.350 (0.139, 0.879) | 0.025 | 0.076 (0.021, 0.282) | <0.001 | ||
| Single renal cyst | 0.098 (0.006, 1.628) | 0.105 | 0.987 (0.366, 2.660) | 0.980 | 0.129 (0.029, 0.575) | 0.007 | ||
| Multiple renal cysts | 1 | – | 1 | – | 1 | – | ||
Adjusted for AAO, IVSD, LVDd, LVPWD, TC, TG. A P value ≤0.05 was considered as statistically significant. TA-AAD, type A acute aortic dissection; AAO, ascending aorta; IVSD, ventricular septum dimension; LVDD, left ventricular end diastolic dimension; LVPWD, left ventricular posterior-wall dimension; TC, total cholesterol; TG, triglyceride.